Bob Proulx Discusses Imagion's Recent Progress with Boardroom Media

Nov 16, 2019
Posted in: News

Home » Bob Proulx Discusses Imagion's Recent Progress with Boardroom Media

Bob Proulx Discusses Imagion's Recent Progress with Boardroom Media

Nov 16, 2019
Posted in: News

Funds raised in Imagion’s recent Rights Issue will be used to fund the first-in-human trials for the Company’s MagSense technology. Listen to CEO Bob Proulx further discuss Imagion’s progress in this recent interview with Boardroom Media.

Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent

November 5, 2025

FDA Submission of IND for MagSense® HER2 Phase 2 Clinical Trial on Track Q4 2025 Key Highlights: Wayne State University Collaboration Program Delivers Positive and

[Video] The Market Bull – Imagion Biosystems’ Magsense Non-invasive Cancer Detection

October 24, 2025

Video transcript: Advances in treatment for cancer have greatly improved survivability when the cancer is caught early. However, despite global spending of over $100

Imagion Biosystems to present at next Emerging Growth Conference

October 22, 2025

MIAMI, FL — Miami-based Emerging Growth has invited medical-imaging company Imagion Biosystems (ASX: IBX) to present at the next Emerging Growth Conference on October 23,

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Bob Proulx Discusses Imagion's Recent Progress with Boardroom Media

Bob Proulx Discusses Imagion's Recent Progress with Boardroom Media

Related Articles

Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent

[Video] The Market Bull – Imagion Biosystems’ Magsense Non-invasive Cancer Detection

Imagion Biosystems to present at next Emerging Growth Conference

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list